Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – 8 to 10 amino acid residues in defined sequence
Reexamination Certificate
2002-03-08
2009-06-16
Rawlings, Stephen L (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
8 to 10 amino acid residues in defined sequence
C530S300000, C530S350000
Reexamination Certificate
active
07547759
ABSTRACT:
The present invention is directed to variants of antigens comprising folate binding protein epitopes as a composition associated with providing immunity against a tumor in an individual. The variant is effective in inducing cytotoxic T-lymphocytes but preferably not to the extent that they become sensitive to silencing by elimination, such as by apoptosis, or by energy, as in unresponsiveness.
REFERENCES:
patent: 5830755 (1998-11-01), Nishimura et al.
patent: 5846538 (1998-12-01), Cheever et al.
patent: 6153430 (2000-11-01), Pastan et al.
patent: 6514942 (2003-02-01), Ioannides et al.
patent: 2003/0027766 (2003-02-01), Ioannides et al.
patent: 2003/0077248 (2003-04-01), Moriarty et al.
Greenspan et al., (Nat Biotechnol. Oct. 1999;17 (10) :936-937).
Yu et al. (Mol Med. Mar. 2002; 8 (3):137-148).
McCoullough et al. (ILAR J. 2005; 46 (3): 230-240).
Bowie et al. (Science. 1990; 257: 1306-1310).
Holmes (Expert Opinion on Investigational Drugs. 2001, 10: 511-519).
Huard et al. (Int. Immunol. 1997; 9 (11):1701-1707).
Fisk et al. (J. Immunother. Emphasis Tumor Immunol. Nov. 1995: 18 (4): 197-209).
Ruppert et al. (Cell. Sep. 10, 1993; 74 (5): 929-937).
Valmori et al. (J. Immunol. 1998; 163: 6956-6962).
Guichard et al. (J. Med. Chem. 2000; 43: 3803-3808).
Schirle et al. (J. Immunol. Methods. 2001; 257: 1-16).
Anderson et al. (Tissue Antigens. Jun. 2000; 55 (6): 519-531).
Feltkamp et al. (Mol. Immunol. Dec. 1994; 31 (18): 1391-1401).
van der Burg et al. (J. Immunol. May 1, 1996; 156 (9): 3308-3314).
Valmori et al. (Journal of Immunology. 1998; 160: 1750-1758).
Campbell et al. (Cancer Res. Oct. 1991; 51 (19): 5329-5338).
Yamshchikov, et al (Clinical Cancer Research. 2001; 7: 909s-916s).
Bodey et al. (Anticancer Research 20: 2665-2676, 2000).
Ezzell (Journal of NIH Research 7: 46-49, 1995).
Spitler (Cancer Biotherapy 10: 1-3, 1995).
Lee et al. (Journal of Immunology 163:6292-6300, 1999).
Zaks et al. (Cancer Research 58: 4902-4908, 1998).
Gao et al. (Journal of Immunotherapy 23:643-653, 2000).
Lu et al. (J. Controlled Release. 2003; 91; 17-29).
Lollini et al. (Trends in Immunology. Feb. 2003; 24 (2): 62-66).
Gura (Science. 1997; 278:1041-1042).
Saijo et al. (Cancer Sci. Oct. 2004; 95 (10): 772-776).
Forni et al. (Int. Immunopharmacol. 2003; 3: 1151-1158).
Skolnick et al. (Trends in Biotechnology 2000; 18 (1): 34-39).
De Plaen et al. (Immunogenetics. 1994; 40:360-369).
Li, Pei Yong, et al.; Local Concentration of Folate Binding Protein GP38 in Sections of Human Ovarian Carcinoma by In Vitro Quantitative Autoradiography; J Nucl Med 1996; 37:665-672.
Ioannides, Constantin G., et al.; Lymphocytes Infiltrating Ovarian Malignant Ascites: Modulation of IL-2-Induced Proliferation by IL-4 and of Selective Increase in CD8+ T Cells by TNF-a; Lymphokine and Cytokine Research, vol. 10 (4), 1991, pp. 307-315.
Ioannides, Constantin G., et al.; Induction of interleukin—2 receptor by tumor necrosis factor a on cultured ovarian tumor-associated lymphocytes; Cancer Immunol Immunother (1992) 35:83-91.
Ioannides, Constantin G., et al.; Cytotoxic T Cells from Ovarian Malignant Tumors Can Recognize Polymorphic Epithelial Mucin Core Peptides; The Journal of Immunology, vol. 151 (7), pp. 3693-3703, Oct. 1, 1993.
Falk, Kirsten, et al.; Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules; Nature, vol. 351, pp. 290-296, May 23, 1991.
Alexander, Richard B., et al.; Adoptively Transferred Tumor-Infiltrating Lymphocytes Can Cure Established Metastatic Tumor in Mice and Persist Long-Term In Vivo as Functional Memory T Lymphocytes; Journal of Immunotherapy 10:389-397, 1991.
Bednarek, Maria A., et al.; Soluble HLA-A2.1 restricted peptides that are recognized by influenza virus specific cytotoxic T lymphocytes; Journal of Immunological Methods, 139 (1991) 41-47.
Buelow, Roland, et al.; Localization of the immunologic activity in the superantigen staphylococcal enterotoxin B using truncated recombinant fusion proteins; The Journal of Immunology, vol. 148 (1), pp. 1-6, Jan. 1, 1992.
Pietersz, G. A., et al.; Generation of Cellular Immune Responses to Antigenic Tumor Peptides; CMLS Cellular and Molecular Life Sciences 57 (2000) 290-310.
Pardoll, Drew M.; Therapeutic Vaccination for Cancer; Clinical Immunology, vol. 95, No. 1, April, pp. S44-S62. 2000.
Rosenberg, Steven A., The Identification of Cancer Antigens: Impact on the Development of Cancer Vaccines; The Cancer Journal; S142-S149.
Lee, Tom V., et. al.; Identification of Activated Tumor Antigen-Reactive CD8+ Cells in Healthy Individuals; Onocoloy Reports 7: 455-466, 2000.
Dalgleish, AG; Cancer Vaccines; British Journal of Cancer (2000) B2(10), 1619-1624.
Abrams, Scott, et al.; Rational Antigen Modification as a Strategy to Upregulate of Downregulate Antigen Recognition; Immunology 2000, 12:85-91.
Kim, Dong-Kyu, et al.; Folate Binding Protein Peptide 191-199 Presented on Dendritic Cells Can Stimulate CTL from Ovarian and Breast Cancer Patients; Anticancer Research 19:2907-2916 (1999).
Peoples, George E., et al.; Ovarian Cancer-Associaed Lymphocyte Recognition of Folate Binding Protein Peptides; Annals of Surgical Oncology, 5(8): 743-750, Published by Lippincott Williams & Wilkins, copyright 1998 The Society of Surgical Oncology, Inc.
Peoples, George, E., et al.; Vaccine Implications of Folate Binding Protein, a Novel Cytotoxic T Lymphocyte-recognized Antigen System in Epithelial Cancers; Texas Medical Association Library, vol. 5, 4314-4223, Dec. 1999.
Hudson, J. Michael, et al.; Growth and Antigen Recognition of Tumor-Infiltrating Lumphocytes from Human Breast Cancer; Journal of Interferon and Cytokine Research 18:529-536 (1998).
Ioannides, Constantin G., et al.; Cytotoxic T Cell Clones Isolated From Ovarian Tumor-Infiltrating Lymphocytes Recognize Multiple Antigenic Epitopes on Autologous Tumor Cells; The Journal of Immunology, vol. 146 (5), 1700-1707, Mar. 1, 1991.
Ioannides, Constantin G., et al.; T-Cell Recognition of Oncogene Products: A New Straategy for Immunotherapy; Molecular Carcinogenesis 6:77-82 (1992).
Ioannides, Constantin G., et al.; Cytotoxic T Cells Isolated from Ovarian Malignant Ascites.
Kos, Ferdynand J., et al,; Specific epitope-induced conversion of CD8+ memory cells into effector cytotoxic T lymphocytes in vitro: presentation of peptide antigen by CD8+ T cells; Eur. J. Immunol. 1992, 22:1595-1601.
Kim, Dong-Kyu, et al.; The Comparison of Cytotoxic T-Lymphocyte Effects of Dendritic Cells Stimulated by the Folate Binding Protein Peptide Cultured with IL-15 and IL-2 in Solid Tumor, Yonsei Medical Journal, (Sep. 2002), vol. 43, No. 6, pp. 691-700.
National Center for Biotechnology Information GenBank Accession No. 1011184A, submitted Jun. 21, 1996; downloaded Sep. 7, 2004.
National Center for Biotechnology Information GenBank Accession No. 0908212A, submitted May 2, 1996; downloaded Sep. 7, 2004.
National Center for Biotechnology Information GenBank Accession No. CAA44610, submitted Feb. 19, 1992; downloaded Sep. 7, 2004.
National Center for Biotechnology Information GenBank Accession No. CAA83553, submitted Apr. 15, 1994; downloaded Sep. 7, 2004.
National Center for Biotechnology Information GenBank Accession No. AAA74896, submitted Aug. 25, 1995; downloaded Sep. 7, 2004.
National Center for Biotechnology Information GenBank Accession No. AAA49056, submitted Apr. 28, 1993; downloaded Sep. 7, 2004.
National Center for Biotechnology Information GenBank Accession No. AAA37599, submitted Apr. 27, 1993; downloaded Sep. 7, 2004.
National Center for Biotechnology Information GenBank Accession No. AAA37598, submitted Apr. 27, 1993; downloaded Sep. 7, 2004.
National Center for Biotechnology Information GenBank Accession No. AAA37597, submitted Apr. 27, 2003; downloaded Sep. 7, 2004.
National Center for Biotechnology Information GenBank Accession No. AAA37594, submitted Apr. 19, 1994; downloaded Sep. 7, 2004.
National Center for Biotechnology Information GenBan Accession No. AAA37596, submitted Apr. 27, 1993; downloaded Sep. 7, 2004.
National Center for Biotechnology Information GenBank Accession No. AAA37595, submi
Ioannides Constantin G.
Peoples, Jr. George E.
Board of Regents , The University of Texas System
Fulbright & Jaworski LLP
Henry M. Jackson Foundation for the Advancement of Military Medi
Rawlings Stephen L
LandOfFree
Induction of tumor immunity by variants of folate binding... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Induction of tumor immunity by variants of folate binding..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Induction of tumor immunity by variants of folate binding... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4079532